Recent News and Articles on the Keywords: vioxx + mobic + web  Related to the article below (Last Update: 8/7/2008)

FASB's Lawyer Bonanza Wall Street Journal - As we saw with Merck and Vioxx, a company's stock price can jump or fall depending on jury verdicts whose results are impossible to predict. ... The Associated Press Merck To Start Issuing Checks In Vioxx Settlement Hartford Courant, United States - Jul 17, 2008 TRENTON, NJ ? - Merck & Co. will start cutting checks for former users of its withdrawn painkiller Vioxx next month after announcing Thursday that it will ... Merck to start Vioxx payouts in August Seattle Post Intelligencer Summary: Key points of Vioxx deal International Herald Tribune Merck will start payments to Vioxx fund Boston Globe Reuters - Forbes all 389 news articles »  MRK Courts duke it out for Vioxx class action Globe and Mail, Canada - Jul 29, 2008 On Monday, Ontario Superior Court Justice Maurice Cullity certified a national Vioxx class action against Merck Frosst, even though Saskatchewan Chief ... Merck faces Canadian class-action Vioxx case International Herald Tribune Ontario Court Certifies VIOXX National Class Action Canada NewsWire (press release) all 18 news articles »  MRK Toxic Drugs, Toxic System: Sociologist Predicts Drug Disasters Science Daily (press release) - Aug 4, 2008 5, 2008) ? Americans are likely to be exposed to unacceptable side effects of FDA-approved drugs such as Vioxx in the future because of fatal flaws in the ... Marketplace Vioxx payouts may not be enough Marketplace, CA - Aug 4, 2008 Vioxx users who sued Merck will begin to receive payouts from the lawsuit this week. But Dan Grech reports several claimants are saying the money they ... Pharmalot FDA Introduces New Conflict of Interest Rules Newsinferno.com, NY - Recent scandals surrounding the misguided approvals of drugs like Vioxx have raised questions about the FDA advisers and the financial ties - such as a ... FDA strengthens policy on vetting of advisers San Francisco Chronicle all 163 news articles » Wall Street Journal Blogs Should Drugs Be Studied in More Patients Before Approval? Wall Street Journal Blogs, NY - Aug 5, 2008 The Duke work suggests that a modestly bigger clinical test might have found problems with Vioxx before the drug hit the market. Bigger studies cost more ... Family fights US drugs firm over mum?s death Essex Echo, UK - June Congdon, from Rayleigh, died from a heart attack, aged 66, after three years of taking the painkiller Vioxx for her arthritis. ... The FDA's Black Box Forbes, NY - 45 minutes ago It was at a 2000 panel meeting that Nissen first saw data on Merck's Vioxx that led him to co-author a paper in The Journal of the American Medical ...SGP - OTC:SHRGY Ministers back compensation campaign over arthritis drug Vioxx Telegraph.co.uk, United Kingdom - Jul 22, 2008 By Kate Devlin Medical Correspondent More than ?2 billion has been paid out to 44000 Americans who took victims of the painkiller, called Vioxx, which was ...

Mobic linked to higher risk of adverse cardiovascular events than Celebrex and Vioxx

Researchers at the National Yang-Ming University, Taipei, ( Taiwan ) assessed the risk of acute myocardial infarction, angina, stroke and transient ischaemic attack ( TIA ) in long-term users of Rofecoxib ( Vioxx ) and Celecoxib ( Celebrex ), and compared this data with that for those using Meloxicam ( Mobic ).

Patients included in the study had used Celecoxib, Rofecoxib or Meloxicam for at least 180 days.
Data were taken from National Health Insurance database for the period from 2001 to 2003.

In patients without a history of a cardiovascular event within the year before drug treatment began, the overall rates of myocardial infarction, angina, stroke and TIA were 1.1%, 0.6%, 2.0% and 0.6%, respectively.

In those with cardiovascular events in the year before treatment began, the overall rates of myocardial infarction, angina, stroke and TIA were 5.0%, 4.8%, 6.6% and 5.8%, respectively.

Compared with Meloxicam users, Celecoxib users had lower hazard ratios ( HRs ) for the development of myocardial infarction ( HR 0.78 ) and stroke ( HR 0.81 ).
Rofecoxib users were at no higher risk of cardiovascular events than those receiving Meloxicam.

Regardless of treatment, having had a cardiovascular event in the year before treatment began played a significant role in the development of the same cardiovascular event during the prescription period; the hazard ratios associated with having had the same cardiovascular event in the past year, versus not having had such an event, were 3.02 for myocardial infarction, 5.82 for angina, 2.44 for stroke and 7.16 for TIA.

According to authors, patients taking Celecoxib had a lower risk of cardiovascular events than those taking Meloxicam. Patients taking Rofecoxib were not found to be at higher cardiovascular risk than those taking Meloxicam.
The most significant determinant of cardiovascular risk was a history of such cardiovascular disease in the year preceding treatment initiation.
Patients with a history of other medical conditions also appeared to be at higher risk of adverse cardiovascular events.

Source: Drug Safety, 2006